Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Study ID
- NCT03333187
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Bone Marrow Fibrosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Allogeneic stem cell transplantation — PROCEDURE
- Ruxolitinib continuous therapy — DRUG
Study Details
The present study will be a multicenter, prospective phase II-study comparing efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.
Key Dates
- Start date
- Dec 21, 2016
- Status verified
- Mar 2025
- Primary completion
- Oct 7, 2024
- Completion
- Oct 7, 2025
Study Design
- Enrollment
- 87 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm ATreatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
- Active Comparator: Arm BTreatment with Ruxolitinib continuous therapy
Primary Outcome Measure
Event free survival [ Time Frame: 3 years ]